Yves Jongen - Ion Beam Director
| IOBCF Stock | USD 13.58 0.47 3.35% |
Director
Mr. Yves Jongen serves as the Managing Director, Inside Director and Chief Research Officer, representing Technofutur SA, of Ion Beam Applications SA since March 2000. He is also Member of the Nominating Committee of the Company. Before the establishment of the Company in 1986, Mr. Jongen was Director of the Cyclotron Research Center of the Universite Catholique de Louvain . Mr. Jongen graduated cum laude from UCL in 1970 as a Civil Engineer in Electronics and earned an additional certificate in Nuclear Sciences. since 2000.
| Age | 76 |
| Tenure | 24 years |
| Phone | 32 1 047 58 11 |
| Web | https://www.iba-worldwide.com |
Ion Beam Management Efficiency
The company has return on total asset (ROA) of 0.0203 % which means that it generated a profit of $0.0203 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0368 %, meaning that it generated $0.0368 on every $100 dollars invested by stockholders. Ion Beam's management efficiency ratios could be used to measure how well Ion Beam manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Roch Doliveux | Stryker | 64 | |
| Edward Liddy | Abbott Laboratories | 74 | |
| David Wichmann | Boston Scientific Corp | 58 | |
| Michelle Kumbier | Abbott Laboratories | 53 | |
| James Lenehan | Medtronic PLC | 71 | |
| John Stratton | Abbott Laboratories | 60 | |
| Michael Farrell | Zimmer Biomet Holdings | 48 | |
| Stephen MacMillan | Boston Scientific Corp | 56 | |
| Kieran Gallahue | Edwards Lifesciences Corp | 57 | |
| Glenn Tilton | Abbott Laboratories | 72 | |
| Betsy Bernard | Zimmer Biomet Holdings | 65 | |
| Elizabeth Nabel | Medtronic PLC | 69 | |
| Kendall Powell | Medtronic PLC | 66 | |
| Paul LaViolette | Edwards Lifesciences Corp | 63 | |
| Maria Hilado | Zimmer Biomet Holdings | 56 | |
| Randall Hogan | Medtronic PLC | 64 | |
| Andrea Goldsmith | Medtronic PLC | 56 | |
| Patricia Gonzalez | Abbott Laboratories | 49 | |
| Mary Brainerd | Stryker | 67 | |
| Angela Fuente | Edwards Lifesciences Corp | N/A | |
| Scott Donnelly | Medtronic PLC | 59 | |
Management Performance
| Return On Equity | 0.0368 | |||
| Return On Asset | 0.0203 |
Ion Beam Applications Leadership Team
Elected by the shareholders, the Ion Beam's board of directors comprises two types of representatives: Ion Beam inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ion. The board's role is to monitor Ion Beam's management team and ensure that shareholders' interests are well served. Ion Beam's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ion Beam's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Olivier Lechien, Co Director | ||
| Pierre Mottet, Chairman, Chairman of Nomination Committee and Chairman of Compensation Committee | ||
| Soumya Chandramouli, CFO, Member of the Management Board | ||
| Marc Burght, Ex Installation | ||
| Matthias Dierl, Chief Therapy | ||
| Yves Jongen, Founder, Chief Research Officer, Executive Director and Member of Nomination Committee | ||
| Olivier Legrain, CEO and President Executive Director and Member of Nomination Committee | ||
| Frederic Nolf, Group Vice President of Human Resources |
Ion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ion Beam a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0368 | |||
| Return On Asset | 0.0203 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 338.19 M | |||
| Shares Outstanding | 29.15 M | |||
| Shares Owned By Insiders | 29.13 % | |||
| Shares Owned By Institutions | 27.72 % | |||
| Price To Earning | 9.16 X | |||
| Price To Book | 4.53 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Ion Pink Sheet
Ion Beam financial ratios help investors to determine whether Ion Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ion with respect to the benefits of owning Ion Beam security.